Limited time. Limited Seats. 40% off.|Foresight ₹1,40,000 ₹83,898 + 18% GST|12 months of accessGet Foresight
All board jobs

Applications closed

This seat is no longer taking applications — closed on 7 October 2026.

The brief stays here for reference. Seats like it open every week.

See live board seats
India ID ExchangePE/VC-Backed Company Governance

Independent Director — PE-Backed Occupational Health and Workforce Medical Services | Clinical Independence, Employer Contracts and Integration

Confidential private equity-backed healthcare services company Hyderabad· Occupational Health, Workforce Medical Services & Employer Wellness
AuditRiskClinical Quality & Ethics

Closed 7 October 2026

Enterprise context

The company provides workplace-related medical assessments, surveillance, onsite clinical services, emergency support and employee health programmes under contracts with employers. It operates at the boundary between clinical duty, workforce safety, employment decisions and sensitive personal information. The paying customer is usually the employer, but the individual receiving care remains entitled to informed, competent and confidential clinical treatment.

The company is expanding organically and through acquisitions. Scale can create consistent protocols and better access, but it can also amplify errors, conflicted reporting and weak consent. Commercial pressure may encourage rapid assessments, broad declarations of fitness, unnecessary testing or disclosure of information beyond a legitimate purpose. The Board seeks an Independent Director who will defend clinical independence while building disciplined contract economics and integration.

Core Board mandate

The Director will oversee clinical quality, professional accountability, consent, fitness-for-work governance, health-data privacy, onsite emergency readiness, employer contracting, laboratory and referral relationships, acquisition diligence and sponsor-aligned value creation. The appointee must be able to challenge both management and the financial sponsor where growth targets could compromise clinical standards.

The Director will help define what the company may properly communicate to an employer and what must remain within the clinical relationship. The role also requires scrutiny of whether programmes produce meaningful health and safety outcomes or merely generate tests, visits and dashboards.

Strategic and governance agenda

  1. Protect clinical independence. Establish that clinical judgments, referrals and restrictions are made by qualified professionals using appropriate evidence—not to satisfy production, attendance or contract-renewal pressure.

  2. Govern consent and purpose. Ensure individuals understand the assessment, who receives which result, how information will be used and the consequences of declining. Broad employment consent should not authorise unrelated secondary use.

  3. Define fitness-for-work decisions. Review role-demand assessment, temporary restrictions, specialist escalation, reassessment, documentation and appeal. Reports should disclose functional conclusions without unnecessary diagnostic detail.

  4. Assure clinical protocols. Govern medical history, examination, tests, equipment, calibration, interpretation, record completion and deviation. Protocols should be risk-based and updated through accountable clinical leadership.

  5. Strengthen onsite emergency readiness. Examine staffing, medicines, equipment, escalation, transport, communications, drills and integration with the customer's incident command. Contracted presence is not evidence of response capability.

  6. Protect health data. Apply minimum access, clinical segregation, secure employer reporting, retention, deletion, breach response and restrictions on analytics. Sales and account teams should not access identifiable clinical detail.

  7. Govern laboratories and referrals. Review competence, quality events, sample identity, turnaround, pricing, conflicts, abnormal-result escalation and continuity. Referral economics must not influence clinical necessity.

  8. Make contract economics complete. Include clinician time, travel, equipment, consumables, emergency readiness, reporting, supervision, data security, repeat visits, customer-specific requirements and receivable days.

  9. Manage employer expectations. Contracts should define clinical boundaries, customer responsibilities, information sharing, emergency scope, staffing assumptions, access, liability and change control. Commercial teams cannot promise clinical outcomes.

  10. Measure outcomes responsibly. Track follow-up completion, condition detection, restriction review, emergency response, occupational exposure trends and closure of workplace recommendations. Test volume alone is not a health outcome.

  11. Protect clinicians and frontline staff. Review workload, competence, supervision, occupational exposure, fatigue, harassment, escalation rights and professional indemnity. Incentives should not depend primarily on tests or clearances completed.

  12. Create acquisition discipline. Assess clinical records, licences, practitioner credentials, consent, laboratory quality, data security, claims, customer contracts and owner dependence before valuation.

  13. Govern integration. Require early credential verification, protocol alignment, access reset, incident review, customer communication and migration to common clinical and data standards. Synergies must not precede safety controls.

  14. Maintain financial resilience. Stress-test customer loss, clinician shortage, material claim, data breach, delayed integration, regulatory restriction and reimbursement delay. Liquidity must support patient remediation and continuity.

Board decisions requiring independent judgment

The Director will contribute to acquisitions, entry into new clinical services, large employer contracts, onsite staffing models, laboratory partnerships, remote consultation, health analytics, insurance arrangements, debt levels and strategic exit options.

Every new service should identify clinical evidence, practitioner competence, consent, information recipients, escalation, liability, economics and discontinuation pathway. Every acquisition should receive independent clinical and privacy diligence separate from commercial diligence.

Clinical quality and ethics assurance

The Board dashboard should include credentialing gaps; protocol deviations; abnormal-result follow-up; fitness decision appeals; emergency response events; consent exceptions; inappropriate disclosures; data incidents; laboratory corrections; clinical complaints; employee workload; contract contribution; receivables; integration milestones; insurance matters; and unresolved audit findings.

Assurance should combine clinical-record review, consent testing, equipment checks, employer-report sampling, practitioner interviews, laboratory tracing and onsite simulation. The Clinical Quality and Ethics Committee must be able to receive concerns directly from clinicians and affected individuals without commercial filtering.

Candidate profile

Candidates should have at least 22 years of senior experience across healthcare delivery, occupational medicine, diagnostics, employer health, clinical governance, insurance, data protection, audit, finance or private equity portfolio oversight. At least one dimension of the candidate's career should demonstrate direct responsibility for clinical quality, regulated health operations or independent healthcare governance.

Suitable candidates may include former healthcare CEOs, medical directors, clinical-quality leaders, CFOs, risk officers, payer executives, operating partners or Audit Committee Chairs. The candidate must be able to protect professional standards while understanding enterprise customers, acquisition economics and distributed service delivery.

Eligibility, independence and conflicts

Active inclusion in the IICA Independent Directors Databank is mandatory. The appointee must remain independent of the sponsor, founders, management and major customers. Relationships with employers, healthcare providers, laboratories, insurers, pharmaceutical or device suppliers, technology vendors, lenders, investors or acquisition targets must be disclosed.

The role may not be used to generate clinical referrals, insurance placement, diagnostic volume, consulting work or transactions for a connected party. Enhanced confidentiality will apply to clinical and employer information.

First 100-day priorities

  • Observe onsite and clinic-based services and trace representative clinical pathways.
  • Review serious incidents, fitness disputes, consent exceptions, disclosures and abnormal-result follow-up.
  • Examine practitioner credentialing, laboratory oversight and emergency-readiness evidence.
  • Reconstruct economics for major contracts after full clinical and data obligations.
  • Assess recent acquisitions against the common quality and privacy baseline.
  • Establish independent escalation thresholds for clinical, ethical and data concerns.

First-year outcomes

Success should mean demonstrable clinical independence, clearer fitness-for-work governance, protected health data, outcome-led reporting, complete contract economics and acquisitions integrated to a single quality standard. The company should create value because it earns trust from both employers and individuals—not because one party's interests are allowed to dominate the other's.

New to Pharma & Healthcare boards?

What these boards look for, how the committees are composed, what the seats pay, and the eligibility rules that apply.

Seats like this, open now

India ID ExchangeMedium Term

Audit Committee Chair — Digital Trust, Revenue Integrity and Platform Resilience

Confidential listed technology and trust-services company Mumbai· Technology and Digital Services
Current Listing Foresight Priority PeriodAudit Committee Chair & Financial Expert First-timer eligibilityForesight shows whether this board will consider a first-time independent director, before you spend an application.Click to get Foresight →AuditNRCCSR

The business delivers technology and trust-sensitive services. Its financial result depends on contracts, platform availability, protected information, customer acceptance and continuing service obligations. The Audit Committee Chair must therefore examine not only whether the…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 40d 15:16:55· 29 December 2026 at 11:59 pm IST
Posted 30 OctApply
India ID ExchangeMedium Term

NRC Chair and Risk Member — Listed Specialist Finance Institution

Confidential listed specialist finance institution Delhi NCR· Banking and Financial Services
Current Listing Foresight Priority PeriodSector-Regulated Independent DirectorNRCRiskStakeholders

The independent director will chair NRC and serve on Risk, Stakeholders Relationship and CSR. The mandate is to ensure that leadership, incentives and succession can withstand the institution's aggregate risk before individual businesses use their own metrics to explain it away.…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 39d 15:16:55· 28 December 2026 at 11:59 pm IST
Posted 30 OctApply
India ID ExchangeMedium Term

NRC Chair — Process Manufacturing, Succession and Long-Horizon Capability

Confidential listed process-manufacturing company Noida· Process Manufacturing
Current Listing Foresight Priority PeriodNRC Chair & Board SuccessionNRC

The company combines process engineering, manufacturing, resource stewardship, supply networks and customer relationships that mature over long cycles. The NRC Chair must ensure that leadership succession and reward preserve capability across cycles rather than optimise only the…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 38d 15:16:55· 27 December 2026 at 11:59 pm IST
Posted 29 OctApply
India ID ExchangeMedium Term

NRC Chair and Risk Member — Financial Markets Leadership and Conduct

Confidential listed financial-services company Mumbai· Banking and Financial Services
Current Listing Foresight Priority PeriodNRC Chair & Board SuccessionNRCRiskAudit

The seat chairs NRC and participates in Risk and Audit. The Board needs a director who can judge whether leadership, incentives and control-function stature support fiduciary conduct through changing markets. In financial services, stakeholder confidence can alter flows,…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 36d 15:16:55· 25 December 2026 at 11:59 pm IST
Posted 28 OctApply